Navigation Links
Blocking tumor-associated macrophages decreased glioblastoma's growth & extended survival in mice
Date:12/15/2013

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology (ASCB) annual meeting in New Orleans.

The rates of apoptosis, or programmed cell death, were higher in the mice treated with the experimental agent than in the untreated animals that also had high-grade glioblastomas, said Johanna Joyce, Ph.D., of the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. As a result, the drug-treated laboratory mice survived many months longer than the untreated animals with the same cancer.

The experimental drug blocks cell receptors for colony-stimulating factor-1 (CSF-1R), which is essential to the differentiation and survival of tumor-associated macrophages and microglia (TAMS), which are the brain's front-line immune defense cells. The microenvironment that surrounds brain tumors contains many macrophages with this receptor.

Glioblastoma multiforme (GBM) is the most common and the most deadly adult primary brain tumor, with an average survival of just 14 months following diagnosis. Even with aggressive treatment by surgery, radiation and chemotherapy, most therapeutic approaches targeting the glioma cells in GBM fail.

Faced with this bleak picture, Dr. Joyce and colleagues MSKCC looked for an alternative strategy and turned to the cancer's cellular neighbors, the non-tumor cells that are part of the glioma microenvironment. In particular, they zeroed in on tumor-associated macrophages and TAMs.

When Dr. Joyce's lab used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse model of GBM, the treated mice survived many months longer than the control cohort. Their established, high-grade gliomas regressed in proliferation and maligna
'/>"/>

Contact: Cathy Yarbrough
cyarbrough@ascb.org
858-243-1814

John Fleischman
jfleischman@ascb.org

American Society for Cell Biology
Source:Eurekalert


Page: 1 2

Related biology news :

1. Pathogen study explores blocking effect of E. coli O157:H7 protein
2. Newly identified proteins make promising targets for blocking graft-vs.-host disease
3. Study suggests way to fight therapy resistant leukemia by blocking DNA repair
4. Blocking overactive receptor in Alzheimers recovers memory loss and more
5. Drug reduces fat by blocking blood vessels
6. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
7. Study finds depletion of alveolar macrophages linked to bacterial super-infections
8. Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth
9. High cholesterol fuels the growth and spread of breast cancer
10. Methylation signaling controls angiogenesis and cancer growth
11. Plant cell architecture: Growth toward a light source
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Haven, Conn.Paleontologists have discovered a new species of dinosaur with ... skull, according to a paper published in the April issue ... species was a plant-eating dinosaur about as big as a ... said Nicholas Longrich of Yale University, lead author of the ...
... RIVERSIDE, Calif. Robert Luck , a professor of ... California Citrus Quality Council,s prestigious Albert G. Salter Memorial Award ... Luck is a leading expert in the research ... "This is a truly deserving award for Professor Luck ...
... The Marine Protected Areas Federal Advisory Committee will meet ... Charleston, S.C. The committee advises the Department of Commerce ... to the national system of MPAs. The ... includes integrating the national MPA system with the Coastal ...
Cached Biology News:New bony-skulled dinosaur species discovered in Texas 2UC Riverside entomologist recognized for research in citrus entomology 2
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:2/27/2015)... Md. (PRWEB) February 27, 2015 ... Chromatography system (Nexera UC) can sequentially analyze up ... separation combined with high-sensitivity detection of targets by ... is designed to fulfill the measurement requirements of ... in food products, drug delivery and search for ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... CAMBRIDGE, Mass., Oct. 31 Idenix,Pharmaceuticals, Inc., (Nasdaq: ... results for the third quarter of 2007 on Tuesday, ... In conjunction with the issuance of the press release, ... ET on Tuesday, November,6, 2007 to discuss the company,s ...
... tech development, opportunities for business growth, COLUMBUS, ... Ohio,colleges and universities increased academic research expenditures in ... than ever into high,technology R&D sectors throughout the ... high tech research, development and,commercialization, especially in the ...
... SAN FRANCISCO, Oct. 31 Medivation, Inc.,(Nasdaq: MDVN ... chief,executive officer, will present at the Acumen BioFin Rodman ... at 11:15 a.m. Eastern,Time at the New York Palace ... Medivation and its clinical,development programs for Dimebon(TM) for Alzheimer,s ...
Cached Biology Technology:Ohio Academic Institutions Increase Research and Development Investments 2Ohio Academic Institutions Increase Research and Development Investments 3Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
Request Info...
... The Cellject Uno Electroporator is ... for producing optimum efficiencies in bacterial ... simply selects one of two voltages ... or four mm cuvettes. On pressing ...
Request Info...
Biology Products: